InVivo falls as spinal cord injury treatment device fails study

InVivo Therapeutics Holdings

09/03/2023 16:57

** Shares of medical equipment maker InVivo Therapeutics
Holdings Corp  NVIV.O  fall 45.1% to $1.20
    ** NVIV reports its experimental acute spinal cord injury
(SCI) treatment device, made of naturally dissolving stents,
failed to achieve primary goal in a 20-patient study
    ** Test results from the implantation device did not align
with main goal of defined improvement on standard impairment
scale vs a control group that received standard-of-care surgery 
    ** Following study results, NVIV to evaluate full study data
set and strategic options for the company
    ** Co is developing the device, Neuro-Spinal Scaffold, to
provide meaningful benefit in acute thoracic SCI patients,
either alone or in combination with other technologies 
    ** Including session moves, stock down 50.2% so far in 2023

 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))